TB being one of the deadliest diseases and second most common infectious cause of
deaths, poses the severe threat to global health. The extended duration of therapy owing to …

Delamanid, bedaquiline, and pretomanid have been recently added in the anti-tuberculosis
(anti-TB) treatment regimens and have emerged as potential solutions for combating drug …

A DNA damage-inducible mutagenic gene cassette has been implicated in the emergence
of drug resistance in Mycobacterium tuberculosis during anti-tuberculosis (TB) …

Phthiocerol dimycocerosate (PDIM) is an essential virulence lipid of Mycobacterium
tuberculosis. In vitro culturing rapidly selects for spontaneous PDIM-negative mutants that …

In the past two decades, drug candidates with a covalent binding mode have gained the
interest of medicinal chemists, as several covalent anticancer drugs have successfully …

The inappropriate and inconsistent use of antibiotics in combating multidrug-resistant
bacteria exacerbates their drug resistance through a few distinct pathways. Firstly, these …

Even though the genus Mycobacterium is a diverse group consisting of a majority of
environmental bacteria known as non-tuberculous mycobacteria (NTM), it also contains …

Mycobacterium smegmatis Lhr exemplifies a novel clade of helicases composed of an N-
terminal ATPase/helicase domain (Lhr-Core) and a large C-terminal domain (Lhr-CTD) that …

The development of new drugs to combat bacterial virulence and target specific locations is
a major challenge in the pharmaceutical industry. Multidrug resistance in bacteria can occur …

Despite reinvigorated efforts in Tuberculosis (TB) drug discovery over the past 20 years,
relatively few new drugs and candidates have emerged with clear utility against drug …